Tactical Approaches to Interconverting GPCR Agonists and Antagonists

Journal of Medicinal Chemistry

Volumn 59, Issue 3, 2016, Pages 810-840

  Dosa, Peter I ^a   Amin, Elizabeth Ambrose ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CABERGOLINE; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR AFFECTING AGENT; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; ERGOT ALKALOID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 30; GHRELIN RECEPTOR; HISTAMINE H4 RECEPTOR ANTAGONIST; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; NOCICEPTIN RECEPTOR AGONIST; NOCICEPTIN RECEPTOR ANTAGONIST; PERGOLIDE; RECEPTOR BLOCKING AGENT; SEROTONIN 2B RECEPTOR; SEROTONIN 7 RECEPTOR; VASOPRESSIN V2 RECEPTOR; LIGAND;

BINDING AFFINITY; CHEMICAL MODIFICATION; CHIRALITY; DIASTEREOISOMER; DRUG ANTAGONISM; DRUG CONFORMATION; DRUG RECEPTOR BINDING; ENANTIOMER; HUMAN; HYDROGEN BOND; METHYLATION; NONHUMAN; PARTIAL AGONISM; PHARMACOPHORE; PHOTOAFFINITY LABELING; REVIEW; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84958214372     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00982     Document Type: Review

References (99)

1. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How Many Drug Targets are There? Nat. Rev. Drug Discovery 2006, 5, 993-996 10.1038/nrd2199
2. Salon, J. A.; Lodowski, D. T.; Palczewski, K. The Significance of G Protein-Coupled Receptor Crystallography for Drug Discovery Pharmacol. Rev. 2011, 63, 901-937 10.1124/pr.110.003350
3. McGrath, N. A.; Brichacek, M.; Njardarson, J. T. A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives J. Chem. Educ. 2010, 87, 1348-1349 10.1021/ed1003806
4. Congreve, M.; Langmead, C. J.; Mason, J. S.; Marshall, F. H. Progress in Structure Based Drug Design for G Protein-Coupled Receptors J. Med. Chem. 2011, 54, 4283-4311 10.1021/jm200371q
5. Alexander, S. P. H.; Benson, H. E.; Faccenda, E.; Pawson, A. J.; Sharman, J. L.; Spedding, M.; Peters, J. A.; Harmar, A. J. The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors Br. J. Pharmacol. 2013, 170, 1459-1581 10.1111/bph.12445
6. Kemal, P. Binding and Activity of Opioid Ligands at the Cloned Human Delta, Mu, and Kappa Receptors. In The Delta Receptor; CRC Press: Boca Raton, 2003.
7. Raynor, K.; Kong, H.; Chen, Y.; Yasuda, K.; Yu, L.; Bell, G. I.; Reisine, T. Pharmacological Characterization of the Cloned kappa-, delta-, and mu-opioid Receptors Mol. Pharmacol. 1994, 45, 330-334
8. Fuerst, S.; Hosztafi, S.; Friedmann, T. Structure-Activity Relationships of Synthetic and Semisynthetic Opioid Agonists and Antagonists Curr. Med. Chem. 1995, 1, 423
9. Lasagna, L.; De Kornfeld, T. J. Analgesic Potency of Normorphine in Patients with Postoperative Pain J. Pharmacol. Exp. Ther. 1958, 124, 260-263
10. Sugg, E. E., Nonpeptide Agonists for Peptide Receptors: Lessons from Ligands. In Annual Reports in Medicinal Chemistry; James, A. B., Ed.; Academic Press: New York, 1997; Vol. 32, Chapter 28, pp 277-283.
11. Fujioka, M.; Omori, N. Subtleties in GPCR Drug Discovery: a Medicinal Chemistry Perspective Drug Discovery Today 2012, 17, 1133-1138 10.1016/j.drudis.2012.06.010
12. Rudolph, J.; Esler, W. P.; O'Connor, S.; Coish, P. D. G.; Wickens, P. L.; Brands, M.; Bierer, D. E.; Bloomquist, B. T.; Bondar, G.; Chen, L.; Chuang, C.-Y.; Claus, T. H.; Fathi, Z.; Fu, W.; Khire, U. R.; Kristie, J. A.; Liu, X.-G.; Lowe, D. B.; McClure, A. C.; Michels, M.; Ortiz, A. A.; Ramsden, P. D.; Schoenleber, R. W.; Shelekhin, T. E.; Vakalopoulos, A.; Tang, W.; Wang, L.; Yi, L.; Gardell, S. J.; Livingston, J. N.; Sweet, L. J.; Bullock, W. H. Quinazolinone Derivatives as Orally Available Ghrelin Receptor Antagonists for the Treatment of Diabetes and Obesity J. Med. Chem. 2007, 50, 5202-5216 10.1021/jm070071+
13. Ting, P. C.; Umland, S. P.; Aslanian, R.; Cao, J.; Garlisi, C. G.; Huang, Y.; Jakway, J.; Liu, Z.; Shah, H.; Tian, F.; Wan, Y.; Shih, N.-Y. The Synthesis of Substituted Bipiperidine Amide Compounds as CCR3 Ligands: Antagonists versus Agonists Bioorg. Med. Chem. Lett. 2005, 15, 3020-3023 10.1016/j.bmcl.2005.04.054
14. Bergink, V.; Westenberg, H. G. M. Metabotropic Glutamate II Receptor Agonists in Panic Disorder: a Double Blind Clinical Trial with LY354740 Int. Clin. Psychopharmal. 2005, 20, 291-293 10.1097/00004850-200511000-00001
15. Dominguez, C.; Prieto, L.; Valli, M. J.; Massey, S. M.; Bures, M.; Wright, R. A.; Johnson, B. G.; Andis, S. L.; Kingston, A.; Schoepp, D. D.; Monn, J. A. Methyl Substitution of 2-Aminobicyclo[3.1.0]hexane 2,6-Dicarboxylate (LY354740) Determines Functional Activity at Metabotropic Glutamate Receptors: Identification of a Subtype Selective mGlu2 Receptor Agonist J. Med. Chem. 2005, 48, 3605-3612 10.1021/jm040222y
16. Woolley, M. L.; Pemberton, D. J.; Bate, S.; Corti, C.; Jones, D. N. C. The mGlu2 but not the mGlu3 Receptor Mediates the Actions of the mGluR2/3 Agonist, LY379268, in Mouse Models Predictive of Antipsychotic Activity Psychopharmacology 2008, 196, 431-440 10.1007/s00213-007-0974-x
17. Zaveri, N. T.; Jiang, F.; Olsen, C. M.; Deschamps, J. R.; Parrish, D.; Polgar, W.; Toll, L. A Novel Series of Piperidin-4-yl-1,3-Dihydroindol-2-ones as Agonist and Antagonist Ligands at the Nociceptin Receptor J. Med. Chem. 2004, 47, 2973-2976 10.1021/jm034249d
18. Rothman, R. B.; Baumann, M. H.; Savage, J. E.; Rauser, L.; McBride, A.; Hufeisen, S. J.; Roth, B. L. Evidence for Possible Involvement of 5-HT2B Receptors in the Cardiac Valvulopathy Associated with Fenfluramine and Other Serotonergic Medications Circulation 2000, 102, 2836-2841 10.1161/01.CIR.102.23.2836
19. Goernemann, T.; Huebner, H.; Gmeiner, P.; Horowski, R.; Latte, K. P.; Flieger, M.; Pertz, H. H. Characterization of the Molecular Fragment that is Responsible for Agonism of Pergolide at Serotonin 5-Hydroxytryptamine2B and 5-Hydroxytryptamine2A Receptors J. Pharmacol. Exp. Ther. 2007, 324, 1136-1145 10.1124/jpet.107.133165
20. Hofmann, C.; Penner, U.; Dorow, R.; Pertz, H. H.; Jähnichen, S.; Horowski, R.; Latté, K. P.; Palla, D.; Schurad, B. Lisuride, a Dopamine Receptor Agonist With 5-HT2B Receptor Antagonist Properties: Absence of Cardiac Valvulopathy Adverse Drug Reaction Reports Supports the Concept of a Crucial Role for 5-HT2B Receptor Agonism in Cardiac Valvular Fibrosis Clin. Neuropharmacol. 2006, 29, 80-86 10.1097/00002826-200603000-00005
21. Zanettini, R.; Antonini, A.; Gatto, G.; Gentile, R.; Tesei, S.; Pezzoli, G. Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease N. Engl. J. Med. 2007, 356, 39-46 10.1056/NEJMoa054830
22. Kekewska, A.; Hübner, H.; Gmeiner, P.; Pertz, H. H. The Bulky N(6) Substituent of Cabergoline Is Responsible for Agonism of This Drug at 5-Hydroxytryptamine (5-HT)2A and 5-HT2B Receptors and Thus Is a Determinant of Valvular Heart Disease J. Pharmacol. Exp. Ther. 2011, 338, 381-391 10.1124/jpet.111.181255
23. Dosa, P. I.; Ward, T.; Walters, M. A.; Kim, S. W. Synthesis of Novel Analogs of Cabergoline: Improving Cardiovascular Safety by Removing 5-HT2B Receptor Agonism ACS Med. Chem. Lett. 2013, 4, 254-258 10.1021/ml3003814
24. Kenakin, T. Differences Between Natural and Recombinant G Protein-coupled Receptor Systems with Varying Receptor/G Protein Stoichiometry Trends Pharmacol. Sci. 1997, 18, 456-464 10.1016/S0165-6147(97)01136-X
25. Newman-Tancredi, A.; Conte, C.; Chaput, C.; VerriÈLe, L.; Millan, M. J. Agonist and Inverse Agonist Efficacy at Human Recombinant Serotonin 5-HT1A Receptors as a Function of Receptor:G-protein Stoichiometry Neuropharmacology 1997, 36, 451-459 10.1016/S0028-3908(97)00022-1
26. Kalindjian, S. B.; Dunstone, D. J.; Low, C. M. R.; Pether, M. J.; Roberts, S. P.; Tozer, M. J.; Watt, G. F.; Shankley, N. P. Nonpeptide Cholecystokinin-2 Receptor Agonists J. Med. Chem. 2001, 44, 1125-1133 10.1021/jm0010668
27. Kondo, K.; Ogawa, H.; Shinohara, T.; Kurimura, M.; Tanada, Y.; Kan, K.; Yamashita, H.; Nakamura, S.; Hirano, T.; Yamamura, Y.; Mori, T.; Tominaga, M.; Itai, A. Novel Design of Nonpeptide AVP V2 Receptor Agonists: Structural Requirements for an Agonist Having 1-(4-Aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a Template J. Med. Chem. 2000, 43, 4388-4397 10.1021/jm000108p
28. Rodriguez, F.; Rozas, I.; Ortega, J. E.; Erdozain, A. M.; Meana, J. J.; Callado, L. F. Guanidine and 2-Aminoimidazoline Aromatic Derivatives as α2-Adrenoceptor Ligands: Searching for Structure-Activity Relationships J. Med. Chem. 2009, 52, 601-609 10.1021/jm800838r
29. Rivara, S.; Lodola, A.; Mor, M.; Bedini, A.; Spadoni, G.; Lucini, V.; Pannacci, M.; Fraschini, F.; Scaglione, F.; Sanchez, R. O.; Gobbi, G.; Tarzia, G. N-(Substituted-anilinoethyl)amides: Design, Synthesis, and Pharmacological Characterization of a New Class of Melatonin Receptor Ligands J. Med. Chem. 2007, 50, 6618-6626 10.1021/jm700957j
30. Sharma, S. K.; Jones, R. M.; Metzger, T. G.; Ferguson, D. M.; Portoghese, P. S. Transformation of a κ-Opioid Receptor Antagonist to a κ-Agonist by Transfer of a Guanidinium Group from the 5′- to 6′-Position of Naltrindole J. Med. Chem. 2001, 44, 2073-2079 10.1021/jm010095v
31. Kitbunnadaj, R.; Zuiderveld, O. P.; De Esch, I. J. P.; Vollinga, R. C.; Bakker, R.; Lutz, M.; Spek, A. L.; Cavoy, E.; Deltent, M.-F.; Menge, W. M. P. B.; Timmerman, H.; Leurs, R. Synthesis and Structure-Activity Relationships of Conformationally Constrained Histamine H3 Receptor Agonists J. Med. Chem. 2003, 46, 5445-5457 10.1021/jm030905y
32. Wallinder, C.; Sköld, C.; Botros, M.; Guimond, M.-O.; Hallberg, M.; Gallo-Payet, N.; Karlén, A.; Alterman, M. Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands ACS Med. Chem. Lett. 2015, 6, 178-182 10.1021/ml500427r
33. Rice, A. S. C.; Dworkin, R. H.; McCarthy, T. D.; Anand, P.; Bountra, C.; McCloud, P. I.; Hill, J.; Cutter, G.; Kitson, G.; Desem, N.; Raff, M. EMA401, an Orally Administered Highly Selective Angiotensin II Type 2 Receptor Antagonist, as a Novel Treatment for Postherpetic Neuralgia: a Randomised, Double-blind, Placebo-controlled Phase 2 Clinical Trial Lancet 2014, 383, 1637-1647 10.1016/S0140-6736(13)62337-5
34. Murugaiah, A. M. S.; Wu, X.; Wallinder, C.; Mahalingam, A. K.; Wan, Y.; Sköld, C.; Botros, M.; Guimond, M.-O.; Joshi, A.; Nyberg, F.; Gallo-Payet, N.; Hallberg, A.; Alterman, M. From the First Selective Non-Peptide AT2 Receptor Agonist to Structurally Related Antagonists J. Med. Chem. 2012, 55, 2265-2278 10.1021/jm2015099
35. Perlman, S.; Costa-Neto, C. M.; Miyakawa, A. A.; Schambye, H. T.; Hjorth, S. A.; Paiva, A. C. M.; Rivero, R. A.; Greenlee, W. J.; Schwartz, T. W. Dual Agonistic and Antagonistic Property of Nonpeptide Angiotensin AT1 Ligands: Susceptibility to Receptor Mutations Mol. Pharmacol. 1997, 51, 301-311 10.1124/mol.51.2.301
36. Wallez, V.; Durieux-Poissonnier, S.; Chavatte, P.; Boutin, J. A.; Audinot, V.; Nicolas, J.-P.; Bennejean, C.; Delagrange, P.; Renard, P.; Lesieur, D. Synthesis and Structure-Affinity-Activity Relationships of Novel Benzofuran Derivatives as MT2Melatonin Receptor Selective Ligands J. Med. Chem. 2002, 45, 2788-2800 10.1021/jm0005252
37. Gentili, F.; Bousquet, P.; Brasili, L.; Caretto, M.; Carrieri, A.; Dontenwill, M.; Giannella, M.; Marucci, G.; Perfumi, M.; Piergentili, A.; Quaglia, W.; Rascente, C.; Pigini, M. α2-Adrenoreceptors Profile Modulation and High Antinociceptive Activity of (S)-(-)-2-[1-(Biphenyl-2-yloxy)ethyl]-4,5-dihydro-1H-imidazole J. Med. Chem. 2002, 45, 32-40 10.1021/jm0110082
38. Tautermann, C. S. GPCR Structures in Drug Design, Emerging Opportunities with New Structures Bioorg. Med. Chem. Lett. 2014, 24, 4073-4079 10.1016/j.bmcl.2014.07.009
39. Xu, H. E.; Stanley, T. B.; Montana, V. G.; Lambert, M. H.; Shearer, B. G.; Cobb, J. E.; McKee, D. D.; Galardi, C. M.; Plunket, K. D.; Nolte, R. T.; Parks, D. J.; Moore, J. T.; Kliewer, S. A.; Willson, T. M.; Stimmel, J. B. Structural Basis for Antagonist-mediated Recruitment of Nuclear Co-repressors by PPAR[alpha] Nature 2002, 415, 813-817 10.1038/415813a
40. Semple, G.; Fioravanti, B.; Pereira, G.; Calderon, I.; Uy, J.; Choi, K.; Xiong, Y.; Ren, A.; Morgan, M.; Dave, V.; Thomsen, W.; Unett, D. J.; Xing, C.; Bossie, S.; Carroll, C.; Chu, Z.-L.; Grottick, A. J.; Hauser, E. K.; Leonard, J.; Jones, R. M. Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119 J. Med. Chem. 2008, 51, 5172-5175 10.1021/jm8006867
41. Dennis, M. K.; Burai, R.; Ramesh, C.; Petrie, W. K.; Alcon, S. N.; Nayak, T. K.; Bologa, C. G.; Leitao, A.; Brailoiu, E.; Deliu, E.; Dun, N. J.; Sklar, L. A.; Hathaway, H. J.; Arterburn, J. B.; Oprea, T. I.; Prossnitz, E. R. In Vivo Effects of a GPR30 Antagonist Nat. Chem. Biol. 2009, 5, 421-427 10.1038/nchembio.168
42. Bologa, C. G.; Revankar, C. M.; Young, S. M.; Edwards, B. S.; Arterburn, J. B.; Kiselyov, A. S.; Parker, M. A.; Tkachenko, S. E.; Savchuck, N. P.; Sklar, L. A.; Oprea, T. I.; Prossnitz, E. R. Virtual and Biomolecular Screening Converge on a Selective Agonist for GPR30 Nat. Chem. Biol. 2006, 2, 207-212 10.1038/nchembio775
43. Dennis, M. K.; Field, A. S.; Burai, R.; Ramesh, C.; Petrie, W. K.; Bologa, C. G.; Oprea, T. I.; Yamaguchi, Y.; Hayashi, S.-I.; Sklar, L. A.; Hathaway, H. J.; Arterburn, J. B.; Prossnitz, E. R. Identification of a GPER/GPR30 Antagonist with Improved Estrogen Receptor Counterselectivity J. Steroid Biochem. Mol. Biol. 2011, 127, 358-366 10.1016/j.jsbmb.2011.07.002
44. Leopoldo, M.; Berardi, F.; Colabufo, N. A.; Contino, M.; Lacivita, E.; Niso, M.; Perrone, R.; Tortorella, V. Structure-Affinity Relationship Study on N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-Aryl-1-Piperazinealkylamides, a New Class of 5-Hydroxytryptamine7 Receptor Agents J. Med. Chem. 2004, 47, 6616-6624 10.1021/jm049702f
45. Mnie-Filali, O.; Faure, C.; Lambas-Senas, L.; Mansari, M. E.; Belblidia, H.; Gondard, E.; Etievant, A.; Scarna, H.; Didier, A.; Berod, A.; Blier, P.; Haddjeri, N. Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy Neuropsychopharmacology 2011, 36, 1275-1288 10.1038/npp.2011.13
46. Kim, J. J.; Bridle, B. W.; Ghia, J.-E.; Wang, H.; Syed, S. N.; Manocha, M. M.; Rengasamy, P.; Shajib, M. S.; Wan, Y.; Hedlund, P. B.; Khan, W. I. Targeted Inhibition of Serotonin Type 7 (5-HT7) Receptor Function Modulates Immune Responses and Reduces the Severity of Intestinal Inflammation J. Immunol. 2013, 190, 4795-4804 10.4049/jimmunol.1201887
47. Orús, L.; Pérez-Silanes, S.; Oficialdegui, A.-M.; Martínez-Esparza, J.; Del Castillo, J.-C.; Mourelle, M.; Langer, T.; Guccione, S.; Donzella, G.; Krovat, E. M.; Poptodorov, K.; Lasheras, B.; Ballaz, S.; Hervías, I.; Tordera, R.; Del Río, J.; Monge, A. Synthesis and Molecular Modeling of New 1-Aryl-3-[4-arylpiperazin-1-yl]-1-propane Derivatives with High Affinity at the Serotonin Transporter and at 5-HT1A Receptors J. Med. Chem. 2002, 45, 4128-4139 10.1021/jm0111200
48. Reid, R. C.; Yau, M.-K.; Singh, R.; Hamidon, J. K.; Lim, J.; Stoermer, M. J.; Fairlie, D. P. Potent Heterocyclic Ligands for Human Complement C3a Receptor J. Med. Chem. 2014, 57, 8459-8470 10.1021/jm500956p
49. Becker, D. P.; Flynn, D. L.; Moormann, A. E.; Nosal, R.; Villamil, C. I.; Loeffler, R.; Gullikson, G. W.; Moummi, C.; Yang, D.-C. Pyrrolizidine Esters and Amides as 5-HT4 Receptor Agonists and Antagonists J. Med. Chem. 2006, 49, 1125-1139 10.1021/jm0509501
50. Cole, D. C.; Lennox, W. J.; Lombardi, S.; Ellingboe, J. W.; Bernotas, R. C.; Tawa, G. J.; Mazandarani, H.; Smith, D. L.; Zhang, G.; Coupet, J.; Schechter, L. E. Discovery of 5-Arylsulfonamido-3- (pyrrolidin-2-ylmethyl)-1H-indole Derivatives as Potent, Selective 5-HT6 Receptor Agonists and Antagonists J. Med. Chem. 2005, 48, 353-356 10.1021/jm049243i
51. Liu, Z.; Zhang, H.; Ye, N.; Zhang, J.; Wu, Q.; Sun, P.; Li, L.; Zhen, X.; Zhang, A. Synthesis of Dihydrofuroaporphine Derivatives: Identification of a Potent and Selective Serotonin 5-HT1A Receptor Agonist J. Med. Chem. 2010, 53, 1319-1328 10.1021/jm9015763
52. Hadac, E. M.; Dawson, E. S.; Darrow, J. W.; Sugg, E. E.; Lybrand, T. P.; Miller, L. J. Novel Benzodiazepine Photoaffinity Probe Stereoselectively Labels a Site Deep within the Membrane-Spanning Domain of the Cholecystokinin Receptor J. Med. Chem. 2006, 49, 850-863 10.1021/jm049072h
53. Jiang, W.; Tran, J. A.; Tucci, F. C.; Fleck, B. A.; Hoare, S. R.; Markison, S.; Wen, J.; Chen, C. W.; Marinkovic, D.; Arellano, M.; Foster, A. C.; Chen, C. Synthesis and Characterization of Pyrrolidine Derivatives as Potent Agonists of the Human Melanocortin-4 Receptor Bioorg. Med. Chem. Lett. 2007, 17, 6546-6552 10.1016/j.bmcl.2007.09.079
54. Chen, C.; Jiang, W.; Tran, J. A.; Tucci, F. C.; Fleck, B. A.; Markison, S.; Wen, J.; Madan, A.; Hoare, S. R.; Foster, A. C.; Marinkovic, D.; Chen, C. W.; Arellano, M.; Saunders, J. Identification and Characterization of Pyrrolidine Diastereoisomers as Potent Functional Agonists and Antagonists of the Human Melanocortin-4 Receptor Bioorg. Med. Chem. Lett. 2008, 18, 129-136 10.1016/j.bmcl.2007.10.115
55. Mann, A., Conformational Restriction and/or Steric Hindrance in Medicinal Chemistry. In The Practice of Medicinal Chemistry, 3rd ed.; Wermuth, C. G., Ed.; Academic Press: New York, 2008; Chapter 17, pp 363-379.
56. Le Bourdonnec, B.; Goodman, A. J.; Michaut, M.; Ye, H.-F.; Graczyk, T. M.; Belanger, S.; Herbertz, T.; Yap, G. P. A.; DeHaven, R. N.; Dolle, R. E. Elucidation of the Bioactive Conformation of the N-Substituted trans-3,4-Dimethyl-4-(3-hydroxyphenyl)piperidine Class of μ-Opioid Receptor Antagonists J. Med. Chem. 2006, 49, 7278-7289 10.1021/jm060486f
57. Gao, Z.-G.; Kim, S.-K.; Biadatti, T.; Chen, W.; Lee, K.; Barak, D.; Kim, S. G.; Johnson, C. R.; Jacobson, K. A. Structural Determinants of A3 Adenosine Receptor Activation: Nucleoside Ligands at the Agonist/Antagonist Boundary J. Med. Chem. 2002, 45, 4471-4484 10.1021/jm020211+
58. Savall, B. M.; Edwards, J. P.; Venable, J. D.; Buzard, D. J.; Thurmond, R.; Hack, M.; McGovern, P. Agonist/Antagonist Modulation in a Series of 2-Aryl Benzimidazole H4 Receptor Ligands Bioorg. Med. Chem. Lett. 2010, 20, 3367-3371 10.1016/j.bmcl.2010.04.017
59. Miura, S.-i.; Feng, Y.-H.; Husain, A.; Karnik, S. S. Role of Aromaticity of Agonist Switches of Angiotensin II in the Activation of the AT1 Receptor J. Biol. Chem. 1999, 274, 7103-7110 10.1074/jbc.274.11.7103
60. Burley, S. K.; Petsko, G. A. Amino-Aromatic Interactions in Proteins FEBS Lett. 1986, 203, 139-143 10.1016/0014-5793(86)80730-X
61. Miura, S.-i.; Kiya, Y.; Hanzawa, H.; Nakao, N.; Fujino, M.; Imaizumi, S.; Matsuo, Y.; Yanagisawa, H.; Koike, H.; Komuro, I.; Karnik, S. S.; Saku, K. Small Molecules with Similar Structures Exhibit Agonist, Neutral Antagonist or Inverse Agonist Activity toward Angiotensin II Type 1 Receptor PLoS One 2012, 7, e37974 10.1371/journal.pone.0037974
62. Piergentili, A.; Quaglia, W.; Giannella, M.; Bello, F. D.; Bruni, B.; Buccioni, M.; Carrieri, A.; Ciattini, S. Dioxane and Oxathiane Nuclei: Suitable Substructures for Muscarinic Agonists Bioorg. Med. Chem. 2007, 15, 886-896 10.1016/j.bmc.2006.10.040
63. Del Bello, F.; Barocelli, E.; Bertoni, S.; Bonifazi, A.; Camalli, M.; Campi, G.; Giannella, M.; Matucci, R.; Nesi, M.; Pigini, M.; Quaglia, W.; Piergentili, A. 1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3Muscarinic Receptor Antagonists J. Med. Chem. 2012, 55, 1783-1787 10.1021/jm2013216
64. Sawada, Y.; Kayakiri, H.; Abe, Y.; Mizutani, T.; Inamura, N.; Asano, M.; Hatori, C.; Aramori, I.; Oku, T.; Tanaka, H. Discovery of the First Non-Peptide Full Agonists for the Human Bradykinin B2 Receptor Incorporating 4-(2-Picolyloxy)quinoline and 1-(2-Picolyl)benzimidazole Frameworks J. Med. Chem. 2004, 47, 2853-2863 10.1021/jm030468n
65. Sawada, Y.; Kayakiri, H.; Abe, Y.; Mizutani, T.; Inamura, N.; Asano, M.; Aramori, I.; Hatori, C.; Oku, T.; Tanaka, H. A New Class of Nonpeptide Bradykinin B2 Receptor Ligand, Incorporating a 4-Aminoquinoline Framework. Identification of a Key Pharmacophore To Determine Species Difference and Agonist/Antagonist Profile J. Med. Chem. 2004, 47, 2667-2677 10.1021/jm030326t
66. Asano, M.; Hatori, C.; Sawai, H.; Johki, S.; Inamura, N.; Kayakiri, H.; Satoh, S.; Abe, Y.; Inoue, T.; Sawada, Y.; Mizutani, T.; Oku, T.; Nakahara, K. Pharmacological Characterization of a Nonpeptide Bradykinin B2 Receptor Antagonist, FR165649, and Agonist, FR190997 Br. J. Pharmacol. 1998, 124, 441-446 10.1038/sj.bjp.0701813
67. Pasquini, S.; Botta, L.; Semeraro, T.; Mugnaini, C.; Ligresti, A.; Palazzo, E.; Maione, S.; Di Marzo, V.; Corelli, F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 2. Synthesis and Structure-Activity Relationship of Potent and Selective Cannabinoid-2 Receptor Agonists Endowed with Analgesic Activity in Vivo J. Med. Chem. 2008, 51, 5075-5084 10.1021/jm800552f
68. Pasquini, S.; Ligresti, A.; Mugnaini, C.; Semeraro, T.; Cicione, L.; De Rosa, M.; Guida, F.; Luongo, L.; De Chiaro, M.; Cascio, M. G.; Bolognini, D.; Marini, P.; Pertwee, R.; Maione, S.; Marzo, V. D.; Corelli, F. Investigations on the 4-Quinolone-3-carboxylic Acid Motif. 3. Synthesis, Structure-Affinity Relationships, and Pharmacological Characterization of 6-Substituted 4-Quinolone-3-carboxamides as Highly Selective Cannabinoid-2 Receptor Ligands J. Med. Chem. 2010, 53, 5915-5928 10.1021/jm100123x
69. Cascio, M. G.; Bolognini, D.; Pertwee, R. G.; Palazzo, E.; Corelli, F.; Pasquini, S.; Di Marzo, V.; Maione, S. In Vitro and in Vivo Pharmacological Characterization of Two Novel Selective Cannabinoid CB2 Receptor Inverse Agonists Pharmacol. Res. 2010, 61, 349-354 10.1016/j.phrs.2009.11.011
70. Tran, J. A.; Pontillo, J.; Arellano, M.; White, N. S.; Fleck, B. A.; Marinkovic, D.; Tucci, F. C.; Lanier, M.; Nelson, J.; Saunders, J.; Foster, A. C.; Chen, C. Identification of Agonists and Antagonists of the Human Melanocortin-4 Receptor from Piperazinebenzylamines Bioorg. Med. Chem. Lett. 2005, 15, 833-837 10.1016/j.bmcl.2004.10.096
71. Xi, N.; Hale, C.; Kelly, M. G.; Norman, M. H.; Stec, M.; Xu, S.; Baumgartner, J. W.; Fotsch, C. Synthesis of Novel Melanocortin 4 Receptor Agonists and Antagonists Containing a Succinamide Core Bioorg. Med. Chem. Lett. 2004, 14, 377-381 10.1016/j.bmcl.2003.10.056
72. Rempel, V.; Volz, N.; Hinz, S.; Karcz, T.; Meliciani, I.; Nieger, M.; Wenzel, W.; Bräse, S.; Müller, C. E. 7-Alkyl-3-benzylcoumarins: A Versatile Scaffold for the Development of Potent and Selective Cannabinoid Receptor Agonists and Antagonists J. Med. Chem. 2012, 55, 7967-7977 10.1021/jm3008213
73. Palusiak, M.; Grabowski, S. J. Methoxy Group as an Acceptor of Proton in Hydrogen Bonds J. Mol. Struct. 2002, 642, 97-104 10.1016/S0022-2860(02)00406-4
74. Demange, L.; Boeglin, D.; Moulin, A.; Mousseaux, D.; Ryan, J.; Bergé, G.; Gagne, D.; Heitz, A.; Perrissoud, D.; Locatelli, V.; Torsello, A.; Galleyrand, J.-C.; Fehrentz, J.-A.; Martinez, J. Synthesis and Pharmacological in Vitro and in Vivo Evaluations of Novel Triazole Derivatives as Ligands of the Ghrelin Receptor. 1 J. Med. Chem. 2007, 50, 1939-1957 10.1021/jm070024h
75. Moulin, A.; Demange, L.; Bergé, G.; Gagne, D.; Ryan, J.; Mousseaux, D.; Heitz, A.; Perrissoud, D.; Locatelli, V.; Torsello, A.; Galleyrand, J.-C.; Fehrentz, J.-A.; Martinez, J. Toward Potent Ghrelin Receptor Ligands Based on Trisubstituted 1,2,4-Triazole Structure. 2. Synthesis and Pharmacological in Vitro and in Vivo Evaluations J. Med. Chem. 2007, 50, 5790-5806 10.1021/jm0704550
76. Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. Molecular Switches" on mGluR Allosteric Ligands That Modulate Modes of Pharmacology Biochemistry 2011, 50, 2403-2410 10.1021/bi200129s
77. Gomez-Santacana, X.; Rovira, X.; Dalton, J. A.; Goudet, C.; Pin, J. P.; Gorostiza, P.; Giraldo, J.; Llebaria, A. A Double Effect Molecular Switch Leads to a Novel Potent Negative Allosteric Modulator of Metabotropic Glutamate Receptor 5 MedChemComm 2014, 5, 1548-1554 10.1039/C4MD00208C
78. Packiarajan, M.; Mazza Ferreira, C. G.; Hong, S.-P.; White, A. D.; Chandrasena, G.; Pu, X.; Brodbeck, R. M.; Robichaud, A. J. N-Aryl Pyrrolidinonyl Oxadiazoles as Potent mGluR5 Positive Allosteric Modulators Bioorg. Med. Chem. Lett. 2012, 22, 5658-5662 10.1016/j.bmcl.2012.06.094
79. Shonberg, J.; Lopez, L.; Scammells, P. J.; Christopoulos, A.; Capuano, B.; Lane, J. R. Biased Agonism at G Protein-Coupled Receptors: The Promise and the Challenges-A Medicinal Chemistry Perspective Med. Res. Rev. 2014, 34, 1286-1330 10.1002/med.21318
80. Morishita, K.-i.; Yakushiji, N.; Ohsawa, F.; Takamatsu, K.; Matsuura, N.; Makishima, M.; Kawahata, M.; Yamaguchi, K.; Tai, A.; Sasaki, K.; Kakuta, H. Replacing Alkyl Sulfonamide with Aromatic Sulfonamide in Sulfonamide-type RXR Agonists Favors Switch Towards Antagonist Activity Bioorg. Med. Chem. Lett. 2009, 19, 1001-1003 10.1016/j.bmcl.2008.11.086
81. DeFalco, J.; Steiger, D.; Gustafson, A.; Emerling, D. E.; Kelly, M. G.; Duncton, M. A. J. Oxime Derivatives Related to AP18: Agonists and Antagonists of the TRPA1 Receptor Bioorg. Med. Chem. Lett. 2010, 20, 276-279 10.1016/j.bmcl.2009.10.113
82. Jiao, X.; Kopecky, D. J.; Fisher, B.; Piper, D. E.; Labelle, M.; McKendry, S.; Harrison, M.; Jones, S.; Jaen, J.; Shiau, A. K.; Escaron, P.; Danao, J.; Chai, A.; Coward, P.; Kayser, F. Discovery and Optimization of a Series of Liver X Receptor Antagonists Bioorg. Med. Chem. Lett. 2012, 22, 5966-5970 10.1016/j.bmcl.2012.07.048
83. DiSalvo, D.; Kuzmich, D.; Bentzien, J.; Regan, J.; Kukulka, A.; Fadra-Khan, T.; Nelson, R.; Harcken, C.; Thomson, D.; Nabozny, G. Substituted Phenyl as a Steroid A-ring Mimetic: Providing Agonist Activity to a Class of Arylsulfonamide Nonsteroidal Glucocorticoid Ligands Bioorg. Med. Chem. Lett. 2013, 23, 6645-6649 10.1016/j.bmcl.2013.10.047
84. Nakayama, M.; Yamada, S.; Ohsawa, F.; Ohta, Y.; Kawata, K.; Makishima, M.; Kakuta, H. Discovery of a Potent Retinoid X Receptor Antagonist Structurally Closely Related to RXR Agonist NEt-3IB ACS Med. Chem. Lett. 2011, 2, 896-900 10.1021/ml200197e
85. Nguyen, N.-H.; Apriletti, J. W.; Baxter, J. D.; Scanlan, T. S. Hammett Analysis of Selective Thyroid Hormone Receptor Modulators Reveals Structural and Electronic Requirements for Hormone Antagonists J. Am. Chem. Soc. 2005, 127, 4599-4608 10.1021/ja0440093
86. Nahoum, V.; Pérez, E.; Germain, P.; Rodríguez-Barrios, F.; Manzo, F.; Kammerer, S.; Lemaire, G.; Hirsch, O.; Royer, C. A.; Gronemeyer, H.; de Lera, A. R.; Bourguet, W. Modulators of the Structural Dynamics of the Retinoid X Receptor to Reveal Receptor Function Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 17323-17328 10.1073/pnas.0705356104
87. Lee, J.; Lee, J.; Kang, M.; Shin, M.; Kim, J.-M.; Kang, S.-U.; Lim, J.-O.; Choi, H.-K.; Suh, Y.-G.; Park, H.-G.; Oh, U.; Kim, H.-D.; Park, Y.-H.; Ha, H.-J.; Kim, Y.-H.; Toth, A.; Wang, Y.; Tran, R.; Pearce, L. V.; Lundberg, D. J.; Blumberg, P. M. N-(3-Acyloxy-2-benzylpropyl)-N′-[4-(methylsulfonylamino)benzyl]thiourea Analogues: Novel Potent and High Affinity Antagonists and Partial Antagonists of the Vanilloid Receptor J. Med. Chem. 2003, 46, 3116-3126 10.1021/jm030089u
88. Fensome, A.; Adams, W. R.; Adams, A. L.; Berrodin, T. J.; Cohen, J.; Huselton, C.; Illenberger, A.; Kern, J. C.; Hudak, V. A.; Marella, M. A.; Melenski, E. G.; McComas, C. C.; Mugford, C. A.; Slayden, O. D.; Yudt, M.; Zhang, Z.; Zhang, P.; Zhu, Y.; Winneker, R. C.; Wrobel, J. E. Design, Synthesis, and SAR of New Pyrrole-Oxindole Progesterone Receptor Modulators Leading to 5-(7-Fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348) J. Med. Chem. 2008, 51, 1861-1873 10.1021/jm701080t
89. Sakamaki, Y.; Inaba, Y.; Yoshimoto, N.; Yamamoto, K. Potent Antagonist for the Vitamin D Receptor: Vitamin D Analogues with Simple Side Chain Structure J. Med. Chem. 2010, 53, 5813-5826 10.1021/jm100649d
90. Appendino, G.; Daddario, N.; Minassi, A.; Moriello, A. S.; De Petrocellis, L.; Di Marzo, V. The Taming of Capsaicin. Reversal of the Vanilloid Activity of N-Acylvanillamines by Aromatic Iodination J. Med. Chem. 2005, 48, 4663-4669 10.1021/jm050139q
91. Sundén, H.; Holland, M. C.; Poutiainen, P. K.; Jääskeläinen, T.; Pulkkinen, J. T.; Palvimo, J. J.; Olsson, R. Synthesis and Biological Evaluation of Second-Generation Tropanol-Based Androgen Receptor Modulators J. Med. Chem. 2015, 58, 1569-1574 10.1021/jm501995n
92. Carroll, F. I.; Lee, J. R.; Navarro, H. A.; Brieaddy, L. E.; Abraham, P.; Damaj, M. I.; Martin, B. R. Synthesis, Nicotinic Acetylcholine Receptor Binding, and Antinociceptive Properties of 2-exo-2-(2′-Substituted-3′-phenyl-5′-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Novel Nicotinic Antagonist J. Med. Chem. 2001, 44, 4039-4041 10.1021/jm015561v
93. Cheung, Y.-Y.; Yu, H.; Xu, K.; Zou, B.; Wu, M.; McManus, O. B.; Li, M.; Lindsley, C. W.; Hopkins, C. R. Discovery of a Series of 2-Phenyl-N-(2-(pyrrolidin-1-yl)phenyl)acetamides as Novel Molecular Switches that Modulate Modes of Kv7.2 (KCNQ2) Channel Pharmacology: Identification of (S)-2-Phenyl-N-(2-(pyrrolidin-1-yl)phenyl)butanamide (ML252) as a Potent, Brain Penetrant Kv7.2 Channel Inhibitor J. Med. Chem. 2012, 55, 6975-6979 10.1021/jm300700v
94. René, O.; Fauber, B. P.; Boenig, G. d. L.; Burton, B.; Eidenschenk, C.; Everett, C.; Gobbi, A.; Hymowitz, S. G.; Johnson, A. R.; Kiefer, J. R.; Liimatta, M.; Lockey, P.; Norman, M.; Ouyang, W.; Wallweber, H. A.; Wong, H. Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action ACS Med. Chem. Lett. 2015, 6, 276-281 10.1021/ml500420y
95. Zhi, L.; Tegley, C. M.; Kallel, E. A.; Marschke, K. B.; Mais, D. E.; Gottardis, M. M.; Jones, T. K. 5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists J. Med. Chem. 1998, 41, 291-302 10.1021/jm9705768
96. Zhi, L.; Ringgenberg, J. D.; Edwards, J. P.; Tegley, C. M.; West, S. J.; Pio, B.; Motamedi, M.; Jones, T. K.; Marschke, K. B.; Mais, D. E.; Schrader, W. T. Development of Progesterone Receptor Antagonists from 1,2-Dihydrochromeno[3,4-f]quinoline Agonist Pharmacophore Bioorg. Med. Chem. Lett. 2003, 13, 2075-2078 10.1016/S0960-894X(03)00256-7
97. Ammazzalorso, A.; Giancristofaro, A.; D'Angelo, A.; Filippis, B. D.; Fantacuzzi, M.; Giampietro, L.; Maccallini, C.; Amoroso, R. Benzothiazole-Based N-(Phenylsulfonyl)amides as a Novel Family of PPARα Antagonists Bioorg. Med. Chem. Lett. 2011, 21, 4869-4872 10.1016/j.bmcl.2011.06.028
98. Giampietro, L.; Ammazzalorso, A.; Giancristofaro, A.; Lannutti, F.; Bettoni, G.; De Filippis, B.; Fantacuzzi, M.; Maccallini, C.; Petruzzelli, M.; Morgano, A.; Moschetta, A.; Amoroso, R. Synthesis and Biological Evaluation of 2-Heteroarylthioalkanoic Acid Analogues of Clofibric Acid as Peroxisome Proliferator-Activated Receptor α Agonists J. Med. Chem. 2009, 52, 6224-6232 10.1021/jm900878u
99. Kern, J. C.; Terefenko, E.; Trybulski, E.; Berrodin, T. J.; Cohen, J.; Winneker, R. C.; Yudt, M. R.; Zhang, Z.; Zhu, Y.; Zhang, P. 5-Aryl Indanones and Derivatives as Non-Steroidal Progesterone Receptor Modulators Bioorg. Med. Chem. Lett. 2009, 19, 6666-6669 10.1016/j.bmcl.2009.10.008